[Esophageal cancer: did combined treatments improve prognosis?].
Prognosis of esophageal cancer is very poor. Five-year survival does not exceed 20% after radical surgery, the best available treatment. Unfortunately, only 40% of the patients are amenable to surgery because of poor general status and/or locoregional extension. Adjuvant treatment did not yield survival improvement. Preoperative radiotherapy (three randomized trials) or postoperative radiotherapy (one randomized trial) showed only a decrease of regional relapses, perhaps only for the nodes negative patients. Neoadjuvant chemotherapy obtains some interesting response rate (20-60%), but there has been no evidence yet for survival improvement. Recently, promising results were presented after combination of radiotherapy and chemotherapy. In this paper, we review the present status of combined treatment for esophageal cancer. Our multicentric group (OSOF) is now completing a phase II trial, that should soon form the basis for a phase III prospective study.
Ganem
G
G
Centre d'oncoradiothérapie et d'hématologie Victor-Hugo, Le Mans, France.
Raoul
Y
Y
Goudier
M J
MJ
Dubray
B
B
Colin
P
P
Extra
J M
JM
Hennequin
C
C
Michel-Langlet
P
P
Vignoud
J
J
Bardet
E
E
D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D011379:Prognosis
Cancer de l'oesophage: les traitements combinés ont-ils amélioré le pronostic?